Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

@article{Dienstmann2014PickingTP,
  title={Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.},
  author={Rodrigo Dienstmann and Jordi Rod{\'o}n and Violeta Serra and Josep Tabernero},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 5},
  pages={1021-31}
}
The frequent activation of the PI3K/AKT/mTOR pathway in cancer, and its crucial role in cell growth and survival, has made it a much desired target for pharmacologic intervention. Following the regulatory approval of the rapamycin analogs everolimus and temsirolimus, recent years have seen an explosion in the number of phosphoinositide 3-kinase (PI3K) pathway inhibitors under clinical investigation. These include: ATP-competitive, dual inhibitors of class I PI3K and mTORC1/2; "pan-PI3K… CONTINUE READING